West Pharmaceutical Services, Inc. WST
408.08 USD +1.09 (+0.27%)
Nov 4, 2026, 2:02 PM EST
405.12 Day range 416.46
230.95 52-week range 416.67
- YTD
- +48.32%
- 1 year
- +42.22%
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 471.00 +15.4% upside
Now 408.08
- Target (low)
- 340.00
- Target (mean)
- 471.00
- Target (high)
- 500.00
Ratings (0m) 16 15 buy · 0 hold · 1 sell
- Strong buy3
- Buy12
- Hold0
- Sell0
- Strong sell1
Recommendation trend
- This month 16
- 1 month ago 17
- 2 months ago 16
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | 2.28 | 2.23 – 2.32 | 2.04 | +11.9% | 825.22M | +2.5% | 12 |
| Next quarter | 2.35 | 2.31 – 2.40 | 2.13 | +10.2% | 859.21M | +1.7% | 6 |
| Current year | 9.46 | 9.40 – 9.63 | 7.29 | +29.8% | 3.42B | +11.3% | 16 |
| Next year | 10.39 | 9.97 – 11.08 | 9.46 | +9.8% | 3.62B | +5.9% | 16 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 30, 2026 | Citigroup | Maintained | Buy | Buy |
| Oct 30, 2026 | TD Cowen | Maintained | Buy | Buy |
| Oct 30, 2026 | Barclays | Maintained | Overweight | Overweight |
| Oct 30, 2026 | Evercore ISI Group | Maintained | Outperform | Outperform |
| Oct 13, 2026 | TD Cowen | Maintained | Buy | Buy |
| Oct 7, 2026 | Barclays | Maintained | Overweight | Overweight |
| Sep 22, 2026 | Morgan Stanley | Upgrade | Equal-Weight | Overweight |
| Sep 9, 2026 | UBS | Maintained | Buy | Buy |
| Aug 3, 2026 | Citigroup | Maintained | Buy | Buy |
| Jul 27, 2026 | Evercore ISI Group | Maintained | Outperform | Outperform |
| Jul 13, 2026 | BNP Paribas | Initiated | — | Outperform |
| Jul 9, 2026 | Morgan Stanley | Maintained | Equal-Weight | Equal-Weight |
| Jul 6, 2026 | Evercore ISI Group | Maintained | Outperform | Outperform |
| Jul 2, 2026 | Keybanc | Maintained | Overweight | Overweight |
| Jun 9, 2026 | Barclays | Upgrade | Equal-Weight | Overweight |
| Jun 2, 2026 | Stephens & Co. | Reiterated | Overweight | Overweight |
| May 29, 2026 | Morgan Stanley | Maintained | Equal-Weight | Equal-Weight |
| Apr 27, 2026 | Barclays | Maintained | Equal-Weight | Equal-Weight |
| Apr 14, 2026 | Barclays | Maintained | Equal-Weight | Equal-Weight |
| Feb 13, 2026 | Barclays | Maintained | Equal-Weight | Equal-Weight |
| Feb 3, 2026 | Evercore ISI Group | Maintained | Outperform | Outperform |
| Dec 2, 2025 | Morgan Stanley | Initiated | — | Equal-Weight |
| Oct 29, 2025 | TD Cowen | Initiated | — | Buy |
| Oct 27, 2025 | Barclays | Maintained | Equal-Weight | Equal-Weight |
| Oct 24, 2025 | UBS | Maintained | Buy | Buy |
| Oct 24, 2025 | Keybanc | Maintained | Overweight | Overweight |
| Oct 23, 2025 | Evercore ISI Group | Maintained | Outperform | Outperform |
| Oct 2, 2025 | Barclays | Maintained | Equal-Weight | Equal-Weight |
| Sep 15, 2025 | Rothschild & Co | Initiated | — | Buy |
| Jul 25, 2025 | UBS | Maintained | Buy | Buy |